Research and Markets: Impax Generics Company Intelligence Report

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/641824/impax_generics_com) has announced the addition of the "Impax Generics Company Intelligence Report" report to their offering.

Impax Laboratories, headquartered in Hayward, California, has existed in its present form since December 1999. The firm has three US sites, and also owns a subsidiary in Taiwan, which was incorporated in June 2007. Routine production is expected to begin here in 2010.

Impax focuses on the development and commercialisation of generic and branded pharmaceuticals. Its generics are marketed through Impax' Global Pharmaceuticals division, whilst branded drugs are marketed through the Impax Pharmaceuticals division. The firm markets and sells its products within the continental United States and in Puerto Rico.

Impax has five major customers: McKesson, Teva Pharmaceutical Industries, DAVA pharmaceuticals, Cardinal Health and AmerisourceBergen. Between them, they accounted for 68% of gross revenues in 2008.

Impax entered into a Strategic Alliance with Teva in June 2001. Problems with recognising revenues from the alliance have caused Impax headaches, with the firm unable to file any financial results for 2004 through to 2007 with the SEC. This led to a cessation of trading in Impax's common stock which lasted until December 2008. Impax has now begun to file results for the missing years.

For the year ended 31st December 2008, Impax reported revenues worth US$210.1 million, 23% down on the prior year. However, Global Pharmaceuticals' sales rose by 12% to US$98.6 million.

This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.

This generics company report will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Products

4. Financial Results

5. Major Developments

6. Contact Details

For more information visit http://www.researchandmarkets.com/research/641824/impax_generics_com

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.